Table 1

Demographic, clinical and biological data of the patients at baseline

Variables

MTX active (n = 13)

(mean ± SD)

Responders (n = 23)

(mean ± SD)

Non-responders (n = 12)

(mean ± SD)

P-value

Age (years)

51.64 ± 10.88

50.36 ± 5.82

52.25 ± 11.09

.762

Sex (men/women)

38.46%/61.54%

33.33%/66.67%

37.50%/62.50%

.809

CRP (mg/dl)

16.61 ± 7.21

14.33 ± 14.10

11.68 ± 10.74

.569

Rheumatoid factor (+/-)

92.30%/7.70

80.00%/20.00%

62.50%/37.50

.283

Anti-CCP (UI/ml)

423.25 ± 296.01

994.60 ± 620.24

329.50 ± 7.50

.075

DAS28

3.71 ± .71

2.64 ± .84

3.20 ± .88

.090

Erosions (+/-)

30.76%/69.24%

60.00%/40.00%

71.40%/28.60%

.518

Onset of Symptoms (months)

9.60 ± 9.10

100.53 ± 66.14

148.14 ± 77.79

.090

HAQ

.78 ± .53

1.18 ± .47

1.31 ± .72

.553

Anti-CCP, anti-cyclic citrullinated peptide antibody; CRP, C-reactive protein; DAS28, Disease Activity Score 28; HAQ, Health Assessment Questionnaire

Chara et al. Arthritis Research & Therapy 2012 14:R175   doi:10.1186/ar3928